Leprosy Reactions by Bilik, Leyla et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Leprosy Reactions
Leyla Bilik, Betul Demir and Demet Cicek
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.72481
Abstract
Sudden changes in immune-mediated response to Mycobacterium leprae antigen are
referred to as leprosy reactions. The reactions manifest as acute inflammatory episodes
rather than chronic infectious course. There are mainly two types of leprosy reactions.
Type 1 reaction is associated with cellular immunity and particularly with the reaction
of T helper 1 (Th1) cells to mycobacterial antigens. This reaction involves exacerbation of
old lesions leading to the erythematous appearance. Type 2 reaction or erythema
nodosum leprosum (ENL) is associated with humoral immunity. It is characterized by
systemic symptoms along with new erythematous subcutaneous nodules.
Keywords: leprosy, type 1 reaction, reversal reaction, type 2 reaction, erythema
nodosum leprosum
1. Introduction
Sudden changes in immune-mediated response to Mycobacterium leprae antigen are refer-
red to as leprosy reactions. The reactions manifest as acute inflammatory episodes rather than
chronic infectious course [1]. These reactions account for about 30–50% of cases with leprosy
[2]. Both patients with low and high load of leprosy bacilli are at risk of developing leprosy
reactions. Leprosy reactions can occur at any time before, during, or after the treatment.
Patients with fewer skin lesions and without nerve involvement are less likely to develop
leprosy reactions. The presence of multiple lesions in close proximity to peripheral nerves,
facial involvement, and presence of nerve thickening without functional impairment are risk
factors for the development of leprosy reactions. Patients developing leprosy reactions are
more likely to develop sequelae or deformities [3]. There are mainly two types of leprosy
reactions. Type 1 reaction involves exacerbation of old lesions leading to the erythematous
appearance. Type 2 reaction is an immune complex-mediated reaction. It is characterized by
systemic symptoms along with new erythematous subcutaneous nodules [4].
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2. Type 1 reaction
2.1. Introduction
Type 1 reaction is a delayed hypersensitivity reaction. It mostly occurs in borderline patients as
well as in patients with lepromatous leprosy (LL) and those with tuberculoid leprosy (TL)
receiving therapy. Reaction can be the first sign of the disease and it often persists for a few
weeks or months [5]. Classically, two subtypes of type 1 reactions have been described; first
subtype is called reversal reactions, false exacerbation reaction or upgrading reactions and this
type of reaction is reversible. Second subtype is called downgrading or downgrading reaction
and it is associated with disease worsening. Upgrading (reversal) reactions occur in patients
receiving therapy, and downgrading reactions occurs in patients who do not receive therapy.
Due to decrease in bacterial load, borderline patients receiving therapy progress to tuberculoid
phase of the disease spectrum. Bacterial load increases in patients who do not receive therapy
and clinical appearance shifts to the lepromatous phase of the disease spectrum due to
impaired cellular immunity [6].
2.2. Pathogenesis
These reactions are associated with cellular immunity and particularly with the reaction of T
helper 1 (Th1) cells to mycobacterial antigens. It has been demonstrated that cytokines derived
from Th1 cells such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-
2 (IL-2), and interferon gamma-Ƴ (IFN-Ƴ) play a more prominent role. High levels of TNF-α,
soluble IL-2 receptors, and adhesion molecules also reflect severity of local inflammation.
Borderline leprosy patients with type 1 reaction show increased expression of TNF-α mRNA
in peripheral nerves and skin. Type 1 reactions are mediated by Th1 lymphocytes and secreted
proinflammatory cytokines IFN-Ƴ and IL-12, and free oxygen radicals [4, 5]. It was demon-
strated that macrophages could initiate neural inflammatory process even in the absence of
bacilli in the neural tissue [7].
2.3. Clinical features
Reversal reaction episodes often occur within the first 6 months of multidrug therapy (MDT)
[8]. After initiation of therapy, skin lesions with manifestations of regression or lesions
appearing as hypochromic macules become erythematous and edematous, and these lesions,
then, become scaled and rarely become ulcerated [9]. The existing lesions show signs of
inflammation, but no new lesions occur. Previously unnoticed or invisible patches may
become prominent. This may give the impression of the development of new lesions. The
lesions are often painless, but tenderness may sometimes be found. The lesions are often
accompanied by edema and neuritis in the extremities [6]. Edema in the hands and feet may
be sometimes the main symptom of reversal reaction. There may be burning pain in the
lesions, pain in the face and extremities, and decrease in muscle strength. Isolated neuritis is
commonly observed within the first 12 months of therapy. Nerve thickening and pain may
occur and preexisting peripheral neuropathy may become prominent (sensory, motor, or
autonomic). Ulnar, median, posterior tibial, fibular, radial, and facial nerves are the most
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commonly involved nerves. The patients may present with the symptoms of neural dysfunc-
tion such as loss of sensation, facial palsy, claw hand, and drop-foot. Hyperesthesia may occur
in palmar and plantar areas, associated with widespread nerve damage [1]. The ability to close
eyelids is lost due to damage in the facial nerves (lagophthalmos) [10]. Neural damage is
important, as it is considered the main cause of deformities and sequelae in the course of
reversal reactions. Neuritis episodes may be severe; however, it sometimes has an insidious
and even painless course, which is called silent neuritis. Silent neuritis is defined as sensory or
motor dysfunction in the absence of skin lesions observed in type 1 and type 2 reactions [11]. It
may cause inflammatory eye diseases, including iritis and scleritis, and it may even result in
blindness. Systemic symptoms such as weakness, fever, bone pain, lymphadenomegaly, joint
pain, and generalized edema are rarely observed and these symptoms indicate the severity of
clinical condition. Furthermore, systemic symptoms are minimal in patients close to the TL
pole of the spectrum and more commonly observed in patients close to the LL pole. Fever is
usually absent and patients’ general condition is good [6, 10].
2.4. Risk factors
The risk of type 1 reaction may increase with vaccination, MDT, pregnancy, puerperality,
infections, stress, trauma, and oral contraceptive use. The extensiveness of skin lesions has
been described as an important risk factor both in patients with low and high bacilli load [1]. It
has been shown that the risk of developing neural damage, along with the risk of developing
reversal reaction, is 10-fold higher in patients in whom three or more body segments are
affected [11]. Facial involvement is a risk factor for the development of reversal reaction, as it
is for lagophthalmos [12]. Although factors which can induce type I reactions are not clearly
known, recent studies have pointed to genetic factors [5]. Identification of the risk factors,
therefore, allows more meticulous follow-up of patients and early treatment [1].
2.5. Histopathology
The type 1 reaction is characterized by edema in the upper dermis and disorganized granulo-
mas. The foreign body giant cells, Langhans giant cells accompanied by epidermal erosion and
spongiosis, and fibroplasia appear in the dermis. The necrosis, ulcer and inflammatory infil-
tration by neutrophils may be observed in severe reaction [13]. The cytology of preexisting
granulomas is differentiated by the presence of large epitheloid cells and decreased number
of bacilli. Inflammatory cells often infiltrate epidermis and increased neural destruction is
observed. The edema inside and around the granulomas results in the damage of surrounding
tissues and nerves [1].
2.6. Treatment
The main goal of treatment in type 1 reaction is to suppress the cellular immunity. Prevention
of nerve damage required early diagnosis and early institution of anti-inflammatory medica-
tions. MDT must be continued during the reactions. Corticosteroids are the most effective
drugs used to treat reversal reaction. Their main effects are to inhibit activation of cellular
immune response and suppress inflammatory response against M. leprae antigens in the skin
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and nerves. Corticosteroids increases vasodilation by inhibiting the release of mediators such
as arachidonic acid (prostaglandins) metabolites and platelet activating factor (PAF), vasoac-
tive amines, neuropeptides, interleukin-1 (IL-1), TNF-α, and nitric oxide (NO). They inhibit
adhesion of neutrophils, eosinophils, and lymphocytes to the endothelial cells, their migration
to the inflammation site, and decrease vascular permeability. They inhibit phagocytosis and
production of oxygen-free radicals [1].
Clinically, corticosteroids change the course of reversal reactions in many ways. They decrease
intraneural and cutaneous edema and promote rapid recovery of the symptoms [1]. Earlier
initiation of corticosteroid treatment can eliminate the risk of permanent neural dysfunction
[3]. Corticosteroids must be continued at immunosuppressive doses for prolonged period. A
prednisolone dose of 40 mg has been suggested as the start dose to control many of the type I
reactions. However, patients with neural involvement require a dose of 1 mg/kg (60 mg) or
sometimes higher doses (2 mg/kg). [14] Prednisolone dose must be reduced only after observ-
ing clinical recovery and tapering the dose to 20 mg/day. Recovery is often occurs within
3 months but may sometimes exceed 6 months. Intravenous methylprednisolone pulse ther-
apy has been used to control reactions. Pulse therapy is indicated in severe reversal reactions
and in cases of acute or chronic neuritis who have previously received oral corticosteroid
therapy for prolonged period. The therapy involves administration intravenous methylpred-
nisolone at a dose of 1 gr/day for consecutive 3 days in the first week and this is followed by a
dose of 1 gr/week for consecutive 4 weeks, and finally 1 gr/month for consecutive 4 months.
Prednisone 0.5 mg/kg/day is administered between the cycles of pulse therapy [15]. The
treatment should be modified with a return to the previous dose in case worsening of clinical
condition. Correct start dose and dose tapering regimen for prednisone must be determined on
a patient basis, and this decision must rely on the follow-up of the loss of sensory functions
and motor examination findings. The recommended duration of treatment is often 4–9 months
in patients with borderline tuberculoid (BT) leprosy, 6–9 months in patients with borderline-
borderline (BB) leprosy, 6–18 months in patients with borderline lepromatous (BL) leprosy;
however, the treatment may last 24 months or longer. Patients with recent neural lesions and
particularly those with less than 6-month duration better respond to therapy compared with
patients in whom therapy is initiated in late periods [1].
Immunosuppressive medications such as azathioprine and cyclosporine can be used alone or
in combination with corticosteroids [16]. Thalidomide is an effective drug used as an alterna-
tive to corticosteroid therapy and it allows long-term disease control [17]. Nerve decompres-
sion surgery has a limited place and it is recommended for patients with permanent pain after
corticosteroid therapy. Surgery can be performed in patients with TL and BT leprosy with
neuralgia and nerve abscesses in whom therapy with immunosuppressive is not feasible [1].
3. Type 2 reaction
3.1. Introduction
Type 2 reaction or erythema nodosum leprosum (ENL) occurs in patients with high bacilli load
as in patients with multibacillar type leprosy (BL and LL) [5]. Type 2 reaction is considered to
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be more complicated than type 1 reaction due to systemic nature and recurrent episodes [4].
The differences between type 1 and type 2 reactions are summarized in Table 1 [1, 3, 4, 6, 10,
13]. Type 2 reaction course is 1–2 weeks, but may occur multiple recurrences over several
months [5]. ENL is identified by Pocaterra et al. as single acute (one ENL episode lasting less
than 6 months, recurrence is not), multiple acute (repeated discrete episodes) or chronic (an
episode lasting for more than 6 months, continuous episodes) [18].
Parameter Type 1 reaction Type 2 reaction
Immunological
response
Type 1 helper cells Type 2 helper cells
Pathogenesis Type IV hypersensitivity reaction (delayed
cell-mediated)
Type III hypersensitivity reaction (immune complex
formation and deposition)
Type of
reaction
Reversal reaction
Downgrading reaction
Erythema nodosum leprosum
Lucio’s phenomenon
Erythema multiforme-like reaction
Clinical
phenotype
Tuberculoid, borderline tuberculoid,
borderline-borderline
Previous treatment (except in downgrading
reactions)
Borderline lepromatosis, lepromatosis
Previous treatment or not
Cutaneous
features
Acute onset of erythema and swelling of
previous lesions
No new lesions
New painful subcutaneous nodules in previously
unaffected skin
Necrotic areas
Polymorphous erythematous plaques
Neurological
features
Painful neuritis with or without loss of
nerve function
Pain or tenderness in one or more nerves
Muscle weakness in the hands, feet, or face
Painful neuritis with or without loss of nerve function
Pain or tenderness in one or more nerves
Muscle weakness in the hands, feet, or face
Systemic
manifestations
Rarely Common (Fever, weakness, lymphadenitis, iridocyclitis,
neuritis, arthritis, dactylitis, orchitis)
Risk factors Multidrug therapy
Vaccination
Pregnancy
Puerperality
Oral contraceptive
Infection
Stress
Trauma
Lepromatous leprosy
Vaccination
Pregnancy
Puerperality
Puberty
Infection
Stress
Recurrence Less likely Most likely
Histopathology Tuberculoid granuloma
Superficial dermal edema
Dermal fibroplasia
Disorganized granuloma and necrosis or
ulceration in severe reactions
Neutrophilic infiltrate in the mid-deep dermis
and subcutaneous tissue
Leukocytoclastic vasculitis of the small and
medium vessels
Treatment Nonsteroidal anti-inflammatory drug
Systemic corticosteroids
Acetylsalicylic acid, pentoxifylline
Systemic corticosteroids
Clofazimine
Thalidomide
Table 1. The differences between type 1 and type 2 reactions [1, 3, 4, 6, 10, 13].
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3.2. Pathogenesis
Type 2 reaction is associated with humoral immunity. This is a type 3 hypersensitivity reaction
associated with the deposition of immunocomplexes produced by binding of antigens released
by the destruction of bacilli with antibodies [6]. Immunocomplexes cannot be phagocytosed
by the macrophages, cleared by the kidneys, and they are deposited on the vessel walls [19].
This reaction is also associated with increased levels of proinflammatory cytokines. Release
of inflammatory cytokines and followed by neutrophilic infiltration contribute to the deve-
lopment of variable characteristic clinical findings depending on the involved organ. In type 2
reaction, vasculitis and/or concurrent panniculitis occurs with inflammatory infiltration by
neutrophils [5].
3.3. Clinical features
Type 2 reaction may occur in the early periods of therapy and even after completion of therapy,
as it takes long time for the body to eliminate dead bacilli in the macrophages. It often occurs in
the first three years after initiation of leprosy treatment. Sudden deterioration in clinical
condition may be observed in patients with LL and rarely in patients with BL leprosy [6]. This
reaction can involve multiple organs and systems. Immunocomplexes accumulate in the circu-
lation and they are deposited in the skin, eyes, joints, lymph nodes, kidneys, liver, spleen, bone
marrow, endothelium, and the testes. The lesions are multiple, bilateral, erythematous, firm,
painful, subcutaneous nodules resembling erythema nodosum that are distributed symmetri-
cally. Pustular, bullous ulcerated, and necrotic types have also been reported. Some nodules
may persist as a chronic painful panniculitis and lead to scar. The target lesions of erythema
multiforme may occur in any region [4, 6]. The lesions more often occur in external surfa-
ces of the body [20]. General symptoms such as fever, weakness, edema, myalgia-arthralgia,
dactylitis, bone tenderness, and lymphadenomegaly are observed prior to the occurrence of or
concurrent with ENL lesions. Iridocyclitis, episcleritis, eye pain (photophobia), orchitis, liver,
or kidney damage can be observed. Neuritis, painful enlarged nerves and nerve function
impairment may occur [4, 5]. Necrosis can occur as a result of vascular thrombosis and
ischemia. Vascular occlusion is probably associated with vasculitis caused by immunocomplex
deposition on the vessel wall and leukocytoclasia. This should not be confused with Lucio’s
phenomenon observed with classical LL. In Lucio’s phenomenon, the majority of the bacilli
infect capillary endothelium, leading to endothelial proliferation, thrombosis, and vascular
occlusion [21]. Laboratory tests show elevated levels of acute phase reactants such as
C-reactive protein (CRP), α1-antitrypsin, α1-acit glycoprotein (AGP), and γ-globulins [22].
3.4. Risk factors
Lepromatous leprosy forms with high bacilli load, vaccination, infection, puberty, pregnancy,
puerperality, with significant hormonal changes occurring in women are risk factors for the
development of type 2 reaction. Emotional and psychological stress and associated immuno-
logical and hormonal changes have been regarded to trigger these reactions; however, this has
yet to be confirmed [4, 10].
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3.5. Histopathology
Two different histopathological variants have been described in ENL. First variant has been
reported by Ridley as “the pink nodule type” or classical ENL (or mild ENL form). Typically,
there are clusters of neutrophils accumulated around the foamy macrophages at the center of
small granulomas. Eosinophils, plasma cells, and mast cells are present. Classical characteris-
tics of vasculitis affecting small- or medium-sized vessels, necrotizing changes, and thrombosis
formation have been reported in almost 25% of the patients. Indeed, vasculitic changes mostly
occur in early lesions. Vasculitic changes involving neutrophilic infiltration, hemorrhage, and
thrombus formation may be severe in necrotizing ENL. Necrosis in epidermis and dermis,
collagen degeneration can be observed and this may result in dermal fibrosis [13]. Intact acid
resistant bacilli (ARB) are found in the lesions of untreated patients, whereas granular and
fragmented ARB are often found in patients receiving therapy. Lucio’s phenomenon must be
histopathologically differentiated from real erythema nodosum, Sweet syndrome, pyoderma
gangrenosum, and deep micotic infections [13, 23].
3.6. Treatment
Type 2 reaction often regresses with addition of clofazimine to the MDT. After the use of
clofazimine-containing MDT, type 2 reaction prevalence has decreased in leprosy patients
under therapy. Suppression of inflammation is the basis of therapy. Bed rest and drugs such as
acetylsalicylic acid, corticosteroids, nonsteroidal anti-inflammatory drug (NSAID), chloroquine,
antimony compounds, pentoxifylline, and thalidomide are used in the treatment [4, 24, 25].
Corticosteroids and thalidomide are still considered the mainstay of therapy in severe cases of
type 2 reaction presenting with orchitis, iridocyclitis with glaucoma, and neuritis that cause
neural dysfunction [14]. Administration of high doses of corticosteroids with pulse therapy
and rapid dose tapering within 2–3 weeks have been deemed appropriate as type 2 reaction is
an episodic disease. If maintenance therapy must be avoided particularly in patients with
chronic recurrent ENL, as long term therapy with prednisolone causes dependence to cortico-
steroid therapy and side effects. Thalidomide seems to be the choice of drug in maintenance
therapy. Action mechanism of thalidomide is not clear. It is thought to be effective in the
inhibition of TNF-α. It has some side effects which do not necessitate discontinuation of
therapy. Neuropathy has been reported in approximately 20–30% of patients. It is often
masked by leprosy neuropathy [26]. It is well tolerated at a dose of 100–300 mg/day in cases
with recurrent disease and it provides prolonged remission [4]. Clinical trials have shown that
thalidomide rapidly controls ENL and it is superior to acetylsalicylic acid and pentoxifylline
therapy. On the other hand, thalidomide is teratogenic when used in early periods of preg-
nancy [25]. Thalidomide analogs chemically resemble thalidomide, but side effects are not the
same. Revlimid and aktimid are promising drugs in this category [27].
Clofazimine is recommended in the treatment of chronic recurrent reactions. Clofazimine is
administered for 12 weeks together with corticosteroids at doses of 100 mg tid, 100 mg bid, or
100 mg/day. Clofazimine is less effective than corticosteroids and it often takes 4–6 weeks to be
fully effective. Addition of clofazimine to the therapy is extremely beneficial in reducing
corticosteroid doses or discontinuation of corticosteroid therapy in patients who have become
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dependent on corticosteroids. The total duration of clofazimine therapy should not exceed
12 months [18].
Corticosteroids and thalidomide are the mainstay of therapy in the control of type II reaction.
Selective cytokine inhibitors and phosphodiesterase type-4 inhibitors with potential TNF-
alpha activity but without T-cell activating effect are new drugs [17].
4. Differential diagnoses
In general, cutaneous drug reactions, local skin infections, relapses, diabetes, Bell’s palsy, rheu-
matoid arthritis, rheumatic fever, and disc prolapse must be taken into consideration in dif-
ferential diagnosis. It may manifest as various cutaneous drug reactions such as urticarial,
lichenoid, exanthematous reactions, erythema nodosum, erythemamultiforme, Stevens-Johnson
syndrome and toxic epidermal necrolysis. The patients usually suffer from itching and burning
in some of these lesions, whereas these symptoms are not observed in patients with leprosy.
Furthermore, new skin lesions do not resemble preexisting lesions. Localized skin infections
developing in patients with leprosy are often confined to a particular body site. The lesions do
not occur bilaterally andmedical history is often remarkable for trauma or insect bites that could
cause an infection. New lesions appear if relapse occurs, and this often has an insidious course
rather than a severe clinical course. Reaction often occurs within the first 3 years after initiation
of leprosy therapy and old lesions exhibit acute pain and tenderness. Diabetic patients are prone
to infections and development of peripheral neuropathy. Furthermore, regulation of blood
glucose is impaired upon administration of corticosteroids. All patients must be screened for
diabetes and referred to an advanced facility if diabetes is diagnosed. Bell’s palsy may mimic
facial paralysis caused by leprosy reactions. These patients do not have nerve thickening,
sensory loss along the nerve projection, and hypopigmented skin lesions. This condition is better
evaluated by the ophthalmologists. In Bell’s paralysis, widening of palpebral fissure is not
associated with the drop of lower eyelid. It occurs in women at childbearing age with rheuma-
toid arthritis, joint pain, joint deformities, fever, skin rash, and multiple organ involvement.
Rheumatoid factor is almost always found to be elevated. However, referral to an advanced
facility may be sometimes required to differentiate rheumatoid arthritis from leprosy reaction.
Patients with rheumatic fever are usually young patients with fever, joint pain, and skin rash for
a short period. These patients have high antistreptolysin O titers and valvular involvement can
be found that cause murmur on auscultation. Patients with disc prolapse may present with acute
onset of neuropathy in the extremities. Patients often report weight lifting in the early periods or
stretching in the back. These patients do not show skin lesions or nerve thickening [23, 28].
5. Conclusion
The reactions can contribute to further deterioration of the quality of life in leprosy. Early
diagnosis of reactions can prevent nerve damage and provide early intervention to systemic
complications.
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